The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

If you have an inflammatory bowel disease (IBD) like Crohn's disease or ulcerative colitis (UC), you might not feel like eating much after a flare-up. But good nutrition plays an essential role in ...

Crohn’s disease and ulcerative colitis (UC) are both types of inflammatory bowel disease (IBD) that share similar symptoms but differ in their affected areas, disease progression, and treatment ...

This approval follows the drug's previous sanction for ulcerative colitis in October 2023 ... a significant aspect of Crohn's disease pathology. The FDA's decision is based on results from ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Omvoh’s safety profile in patients with moderate to severe Crohn’s disease aligns with previous findings in patients with ulcerative colitis. The most common side effects include upper ...

This approval follows the drug's previous sanction for ulcerative colitis in October 2023 ... a significant aspect of Crohn's disease pathology. The FDA's decision is based on results from the Phase 3 ...

At 54 weeks, 25% of children with Crohn's disease and 47% of children with ulcerative colitis or unclassified IBD were in complete remission (OR 2.41, 95% CI 1.15-5.05), reported Dan Turner ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.